Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 1/2008

01.10.2008

Pacemaker and ICD leads: Strategies for long-term management

verfasst von: P. Peter Borek, Bruce L. Wilkoff

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Pacemaker and defibrillator therapy is on the rise as a result of expanding indications. Unfortunately, this trend is associated with an increased number of cardiac device-related complications. Lead failure, device infection and vascular complication are not uncommon and may cause significant patient morbidity and mortality. Furthermore, the considerable variability in the approach to dealing with device-related complications not infrequently leads to additional problems and complications. This review is intended to provide general guidelines and strategies for long-term management of cardiac devices. Proper implantation techniques that focus on primary prevention of complications, as well as, planning for future procedures are essential. The use of sterile techniques and implementation of peri-operative antibiotics are well supported in clinical trials. Additionally, minimizing the amount of implanted hardware and limiting the procedure length have also been shown to decrease the rates of infectious complications. Once device infection is confirmed, the primary objective, short of a few exceptions, should consist of the entire system removal via open surgery or percutaneously and antibiotic therapy before reimplantation. Vascular occlusions are not uncommon; however, in the majority of cases they are asymptomatic. Nonetheless, they pose a significant problem with device reimplantation, especially in the younger patients who will require multiple generator exchanges in the future. Site preservation should, therefore, become the primary objective. This can also be accomplished with the open surgical or percutaneous device removal. The latter is very safe and effective when performed in experienced centers. Finally, lead follow-up must be routinely conducted to identify problematic leads, prevent further reimplantations, and guide future research.
Literatur
1.
Zurück zum Zitat Josephson, M., & Wellens, H. J. (2004). Implantable defibrillators and sudden cardiac death. Circulation, 109, 2685–2691.PubMedCrossRef Josephson, M., & Wellens, H. J. (2004). Implantable defibrillators and sudden cardiac death. Circulation, 109, 2685–2691.PubMedCrossRef
2.
Zurück zum Zitat Hauser, R. G. (2005). The growing mismatch between patient longevity and the service life of implantable cardioverted-defibrillators. Journal of the American College of Cardiology, 45, 2022–2025.PubMedCrossRef Hauser, R. G. (2005). The growing mismatch between patient longevity and the service life of implantable cardioverted-defibrillators. Journal of the American College of Cardiology, 45, 2022–2025.PubMedCrossRef
3.
Zurück zum Zitat The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators (1997). A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New England Journal of Medicine, 337, 1576–1583.CrossRef The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators (1997). A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New England Journal of Medicine, 337, 1576–1583.CrossRef
4.
Zurück zum Zitat Moss, A. J., Zareba, W., Hall, W. J., et al. (2002). Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877–833.PubMedCrossRef Moss, A. J., Zareba, W., Hall, W. J., et al. (2002). Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877–833.PubMedCrossRef
5.
Zurück zum Zitat Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (2000). A randomized study of the prevention of sudden death in patients with coronary artery disease. New England Journal of Medicine, 342, 1300.CrossRef Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (2000). A randomized study of the prevention of sudden death in patients with coronary artery disease. New England Journal of Medicine, 342, 1300.CrossRef
6.
Zurück zum Zitat Kadish, A., Dyer, A., Daubert, J. P., et al. (2004). Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. New England Journal of Medicine, 350, 2151–2158.PubMedCrossRef Kadish, A., Dyer, A., Daubert, J. P., et al. (2004). Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. New England Journal of Medicine, 350, 2151–2158.PubMedCrossRef
7.
Zurück zum Zitat Bardy, G. H., Lee, K. L., Mark, D. B., et al. (2005). Sudden Cardiac Death in Heart Failure Trial. (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225–237.PubMedCrossRef Bardy, G. H., Lee, K. L., Mark, D. B., et al. (2005). Sudden Cardiac Death in Heart Failure Trial. (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225–237.PubMedCrossRef
8.
Zurück zum Zitat Abraham, W. T., Fisher, W. G., Smith, A. L., et al. (2002). MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. New England Journal of Medicine, 346, 1845–1853.PubMedCrossRef Abraham, W. T., Fisher, W. G., Smith, A. L., et al. (2002). MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. New England Journal of Medicine, 346, 1845–1853.PubMedCrossRef
9.
Zurück zum Zitat Linde, C., Braunschweig, F., Gadler, F., Bailleul, C., & Daubert, J. C. (2003). Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the Multisite Stimulation in Cardiomyopathy Study (MUSTIC). American Journal of Cardiology, 91, 1090–1095.PubMedCrossRef Linde, C., Braunschweig, F., Gadler, F., Bailleul, C., & Daubert, J. C. (2003). Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the Multisite Stimulation in Cardiomyopathy Study (MUSTIC). American Journal of Cardiology, 91, 1090–1095.PubMedCrossRef
10.
Zurück zum Zitat Bristow, M. R., Saxon, L. A., Boehmer, J., et al. (2004). Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. New England Journal of Medicine, 350, 2140–2150.PubMedCrossRef Bristow, M. R., Saxon, L. A., Boehmer, J., et al. (2004). Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. New England Journal of Medicine, 350, 2140–2150.PubMedCrossRef
11.
Zurück zum Zitat Cleland, J. G., Daubert, J. C., Erdmann, E., et al. (2005). Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352, 1539–1549.PubMedCrossRef Cleland, J. G., Daubert, J. C., Erdmann, E., et al. (2005). Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352, 1539–1549.PubMedCrossRef
12.
Zurück zum Zitat Page, C. P., Bohen, J. M. A., Fletcher, J. R., McManus, A. T., Solomkin, J. S., & Wittmann, D. H. (1993). Antimicrobial prophylaxis for surgical wounds: Guidelines for clinical care. Archives of Surgery, 128, 79.PubMed Page, C. P., Bohen, J. M. A., Fletcher, J. R., McManus, A. T., Solomkin, J. S., & Wittmann, D. H. (1993). Antimicrobial prophylaxis for surgical wounds: Guidelines for clinical care. Archives of Surgery, 128, 79.PubMed
13.
Zurück zum Zitat Da Costa, A., Kirkorian, G., Cucherat, M., et al. (1998). Antibiotic prophylaxis for permanent pacemaker implantation. A meta-analysis. Circulation, 97, 1796–1801.PubMed Da Costa, A., Kirkorian, G., Cucherat, M., et al. (1998). Antibiotic prophylaxis for permanent pacemaker implantation. A meta-analysis. Circulation, 97, 1796–1801.PubMed
14.
Zurück zum Zitat Klug, D., Balde, M., Pavin, D., Hidden-Lucet, F., Clementy, J., Sadoul, N., PEOPLE Study Group, et al. (2007). Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation, 116(12), 1349–1355 Sep 18.PubMedCrossRef Klug, D., Balde, M., Pavin, D., Hidden-Lucet, F., Clementy, J., Sadoul, N., PEOPLE Study Group, et al. (2007). Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation, 116(12), 1349–1355 Sep 18.PubMedCrossRef
15.
Zurück zum Zitat Bertaglia, E., Zerbo, F., Zardo, S., Barzan, D., Zoppo, F., & Pascotto, P. (2006). Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. Pacing and Clinical Electrophysiology, 29, 29–33.PubMedCrossRef Bertaglia, E., Zerbo, F., Zardo, S., Barzan, D., Zoppo, F., & Pascotto, P. (2006). Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. Pacing and Clinical Electrophysiology, 29, 29–33.PubMedCrossRef
16.
Zurück zum Zitat Anonymous (1992). Antibiotic prophylaxis in surgery. Medical Letter on Drugs and Therapeutics, 34, 5–8, Medline. Anonymous (1992). Antibiotic prophylaxis in surgery. Medical Letter on Drugs and Therapeutics, 34, 5–8, Medline.
17.
Zurück zum Zitat Accorti, P. R. (1994). Leads technology. In I. Siner (Ed.) Implantable Cardioverter Dfibrillator. Armonk, NY: Futura. Accorti, P. R. (1994). Leads technology. In I. Siner (Ed.) Implantable Cardioverter Dfibrillator. Armonk, NY: Futura.
18.
Zurück zum Zitat Mouchawar, G. A., Wolsleger, W. K., Doan, P. D., Causey III, J. D., & Kroll, M. W. (1997). Does an SVC electrode further reduce DFT in a hot-can ICD system? Pacing and Clinical Electrophysiology, 20, 163–167.PubMedCrossRef Mouchawar, G. A., Wolsleger, W. K., Doan, P. D., Causey III, J. D., & Kroll, M. W. (1997). Does an SVC electrode further reduce DFT in a hot-can ICD system? Pacing and Clinical Electrophysiology, 20, 163–167.PubMedCrossRef
19.
Zurück zum Zitat Kay, G. N., Brinker, J. A., Kawanishi, D. T., et al. (1999). Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation, 100, 2344–2352.PubMed Kay, G. N., Brinker, J. A., Kawanishi, D. T., et al. (1999). Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation, 100, 2344–2352.PubMed
21.
Zurück zum Zitat Dorwarth, U., Frey, B., Dugas, M., et al. (2003). Transvenous defibrillation leads: High incidence of failure during long-term follow-up. Journal of Cardiovascular Electrophysiology, 14, 38–43.PubMedCrossRef Dorwarth, U., Frey, B., Dugas, M., et al. (2003). Transvenous defibrillation leads: High incidence of failure during long-term follow-up. Journal of Cardiovascular Electrophysiology, 14, 38–43.PubMedCrossRef
22.
Zurück zum Zitat Gold, M. R., Peters, R. W., Johnson, J. W., & Shorofsky, S. R. (1997). Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing and Clinical Electrophysiology, 20, 208–211.PubMedCrossRef Gold, M. R., Peters, R. W., Johnson, J. W., & Shorofsky, S. R. (1997). Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing and Clinical Electrophysiology, 20, 208–211.PubMedCrossRef
23.
Zurück zum Zitat Tullo, N. G., Saksena, S., Krol, R. B., Mauro, A. M., & Kunecz, D. (1990). Management of complications associated with a fist-generation endocardial defibrillation lead system for implantable cardioverter defibrillators. American Journal of Cardiology, 66, 411–415.PubMedCrossRef Tullo, N. G., Saksena, S., Krol, R. B., Mauro, A. M., & Kunecz, D. (1990). Management of complications associated with a fist-generation endocardial defibrillation lead system for implantable cardioverter defibrillators. American Journal of Cardiology, 66, 411–415.PubMedCrossRef
24.
Zurück zum Zitat Wilkoff, B. L., Belott, P. H., Love, C. J., et al. (2005). Improved extraction of ePTFE and medical adhesive modified defibrillation leads from the coronary sinus and great cardiac vein. Pacing and Clinical Electrophysiology, 28, 205–211.PubMedCrossRef Wilkoff, B. L., Belott, P. H., Love, C. J., et al. (2005). Improved extraction of ePTFE and medical adhesive modified defibrillation leads from the coronary sinus and great cardiac vein. Pacing and Clinical Electrophysiology, 28, 205–211.PubMedCrossRef
25.
Zurück zum Zitat Ellenbogen, K. A., Wood, M. A., Shepard, R. K., et al. (2003). Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. Journal of the American College of Cardiology, 41, 73–80.PubMedCrossRef Ellenbogen, K. A., Wood, M. A., Shepard, R. K., et al. (2003). Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. Journal of the American College of Cardiology, 41, 73–80.PubMedCrossRef
26.
Zurück zum Zitat Chua, J. D., Wilkoff, B. L., Lee, I., Juratli, N., Longworth, D. L., & Gordon, S. M. (2000). Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Annals of Internal Medicine, 133, 604–608.PubMed Chua, J. D., Wilkoff, B. L., Lee, I., Juratli, N., Longworth, D. L., & Gordon, S. M. (2000). Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Annals of Internal Medicine, 133, 604–608.PubMed
27.
Zurück zum Zitat Wilkoff, B. L. (2007). How to treat and identify device infections. Heart Rhythm, 11, 1467–1470.CrossRef Wilkoff, B. L. (2007). How to treat and identify device infections. Heart Rhythm, 11, 1467–1470.CrossRef
28.
Zurück zum Zitat Sticherling, C., Chough, S. P., Baker, R. L., et al. (2001). Prevalence of central venous occlusion in patients with chronic defibrillator leads. American Heart Journal, 141, 813–816.PubMedCrossRef Sticherling, C., Chough, S. P., Baker, R. L., et al. (2001). Prevalence of central venous occlusion in patients with chronic defibrillator leads. American Heart Journal, 141, 813–816.PubMedCrossRef
29.
Zurück zum Zitat Byrd, C. L., Wilkoff, B. L., Love, C. J., et al. (1999). Intravascular extraction of problematic or infected permanent pacemaker leads: 1994–1996. U.S. Extraction Database, MED Institute. Pacing and Clinical Electrophysiology, 22, 1348–1357.PubMedCrossRef Byrd, C. L., Wilkoff, B. L., Love, C. J., et al. (1999). Intravascular extraction of problematic or infected permanent pacemaker leads: 1994–1996. U.S. Extraction Database, MED Institute. Pacing and Clinical Electrophysiology, 22, 1348–1357.PubMedCrossRef
30.
Zurück zum Zitat Bracke, F., Meijer, A., & Van Gelder, B. (2002). Extraction of pacemaker and implantable cardioverter defibrillator leads: Patient and lead characteristics in relation to the requirement of extraction tools. Pacing and Clinical Electrophysiology, 25, 1037–1040.PubMedCrossRef Bracke, F., Meijer, A., & Van Gelder, B. (2002). Extraction of pacemaker and implantable cardioverter defibrillator leads: Patient and lead characteristics in relation to the requirement of extraction tools. Pacing and Clinical Electrophysiology, 25, 1037–1040.PubMedCrossRef
31.
Zurück zum Zitat Kennergren, C., Schaerf, R. H., Sellers, T. D., et al. (2000). Cardiac lead extraction with a novel locking stylet. Journal of Interventional Cardiac Electrophysiology, 4, 591–593.PubMedCrossRef Kennergren, C., Schaerf, R. H., Sellers, T. D., et al. (2000). Cardiac lead extraction with a novel locking stylet. Journal of Interventional Cardiac Electrophysiology, 4, 591–593.PubMedCrossRef
32.
Zurück zum Zitat Gilligan, D. M., & Dan, D. (2001). Excimer laser for pacemaker and defibrillator lead extraction: Techniques and clinical results. Lasers in Medical Science, 16, 113–121.PubMedCrossRef Gilligan, D. M., & Dan, D. (2001). Excimer laser for pacemaker and defibrillator lead extraction: Techniques and clinical results. Lasers in Medical Science, 16, 113–121.PubMedCrossRef
33.
Zurück zum Zitat Wilkoff, B. L., Byrd, C. L., Love, C. J., Hayes, D. L., Sellers, T. D., Schaerf, R., et al. (1999). Pacemaker lead extraction with the laser sheath: Results of the pacing lead extraction with the excimer sheath (PLEXES) trial. Journal of the American College of Cardiology, 33, 1671–1676.PubMedCrossRef Wilkoff, B. L., Byrd, C. L., Love, C. J., Hayes, D. L., Sellers, T. D., Schaerf, R., et al. (1999). Pacemaker lead extraction with the laser sheath: Results of the pacing lead extraction with the excimer sheath (PLEXES) trial. Journal of the American College of Cardiology, 33, 1671–1676.PubMedCrossRef
34.
Zurück zum Zitat Byrd, C. L., Wilkoff, B. L., Love, C. J., Sellers, T. D., & Reiser, C. (2002). Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing and Clinical Electrophysiology, 25, 804–808.PubMedCrossRef Byrd, C. L., Wilkoff, B. L., Love, C. J., Sellers, T. D., & Reiser, C. (2002). Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing and Clinical Electrophysiology, 25, 804–808.PubMedCrossRef
35.
Zurück zum Zitat Ellenbogen, K. A., Wilkoff, B. L., Kay, G. N., & Lau, C. P. (2007). Clinical cardiac pacing, defibrillation, and resynchronization therapy. Philadelphia, PA: Saunders. Ellenbogen, K. A., Wilkoff, B. L., Kay, G. N., & Lau, C. P. (2007). Clinical cardiac pacing, defibrillation, and resynchronization therapy. Philadelphia, PA: Saunders.
Metadaten
Titel
Pacemaker and ICD leads: Strategies for long-term management
verfasst von
P. Peter Borek
Bruce L. Wilkoff
Publikationsdatum
01.10.2008
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 1/2008
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-008-9249-7

Weitere Artikel der Ausgabe 1/2008

Journal of Interventional Cardiac Electrophysiology 1/2008 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.